Large-scale population analysis confirms reassuring safety profile of tirzepatide

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged. Now real-world evidence from the FDA Adverse Event Reporting System (FAERS) database reveals a reassuring safety profile for tirzepatide (TZP).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup